Our October Newsletter
This past month has been a milestone in SOPHiA GENETICS ' journey to transform healthcare. Here’s a recap of our latest achievements, initiatives, and key events that underscore our commitment to data-driven medicine, empowering the community, and advancing patient care.
Introducing “Research Spotlight” by Dr. Jurgi Camblong, Co-Founder & CEO
Dr. Jurgi Camblong , our Co-Founder and CEO, launched the new Research Spotlight series, offering insights on groundbreaking studies that deepen our understanding of complex diseases.
His latest edition, highlighting AML research published in The Lancet Haematology, explores the ways data-driven insights can shape the future of healthcare.
?? Customer Testimonial: RNAtarget Technology
A heartfelt thanks to the team at Microcitemico Pediatric Hospital – A. Cao in Cagliari for sharing how SOPHiA DDM? RNAtarget Technology has transformed their workflow.
The experience from Manuela Badiali, Rita Congiu, and Stefania Murru highlights the role of SOPHiA GENETICS in driving efficiency and precision for the benefit of patients.
?? October is Pink Month!
Throughout October, SOPHiA GENETICS took united action against breast cancer, hosting awareness sessions across our global offices — in Bidart, Pessac, Rolle, and Boston. These events were met with high engagement and creativity, bringing SOPHiANS together with a DIY “paint it pink” station.
Thank you to our customers who rely on the SOPHiA DDM? Platform for breast cancer testing, helping detect crucial biomarkers for both somatic and germline mutations. Together, we keep pushing forward in the fight against breast cancer!
Decoding Rare Diseases, One Variant at a Time
The SOPHiA DDM? Platform complemented by Alamut? Visual Plus offers streamlined Exome analysis workflows (from FASTQ file to variant report) for the efficient identification of genomic variants associated with rare and inherited diseases.
领英推荐
In a single workflow, the SOPHiA DDM? Platform analyzes variants in mtDNA alongside SNVs, Indels, and CNVs in both coding and disease-relevant non-coding regions of nuclear DNA (nDNA).
SOPHiA GENETICS at BioJapan 2024
We marked our first appearance at BioJapan, where we connected with industry leaders and showcased the power of SOPHiA DDM? in transforming healthcare.
Trusted by 780+ healthcare institutions across 70+ countries, our solutions support clinical researchers in making data-backed decisions worldwide.
The Benefits of Matched Tumor-Normal Sequencing
In our latest blog, we dive into the advantages of matched tumor-normal genomic profiling, which helps retain accurate somatic variant calls, reduces noise, and eliminates false positives.
Discover why having a complete picture of a tumor’s genomic makeup is crucial for accurate assessment and informed decision-making.
Invitation to Join our Webinar
Join us for an insightful webinar featuring biologist Silvia Salmoiraghi from ASST Papa Giovanni XXIII Hospital in Bergamo, Italy, as she explores the performance of the NEW SOPHiA DDM? Residual Acute Myeloid (RAM) Solution.
Discover how this innovative solution enhances MRD detection, paving the way for more accurate prognosis while offering better insights for treatment strategies in AML.
If you're as passionate about transforming healthcare as we are, don't miss out on our future updates. ?? Subscribe to our monthly newsletter and stay at the forefront of data-driven medicine.